Last reviewed · How we verify
AXT107 Mid Dose
At a glance
| Generic name | AXT107 Mid Dose |
|---|---|
| Also known as | Gersizangatide |
| Sponsor | AsclepiX Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE1, PHASE2)
- Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (PHASE1, PHASE2)
- Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |